"Obecn\u00E9 kontraindikace pro pod\u00E1v\u00E1n\u00ED p\u0159\u00EDpravku NUMETA ve form\u011B aktivovan\u00E9ho 2komorov\u00E9ho vaku v\u00A0podob\u011B intraven\u00F3zn\u00EDch infuz\u00ED jsou n\u00E1sleduj\u00EDc\u00ED:\nhypersenzitivita na vaje\u010Dn\u00E9, sojov\u00E9 nebo ara\u0161\u00EDdov\u00E9 proteiny nebo kteroukoli l\u00E9\u010Divou nebo pomocnou l\u00E1tku tohoto p\u0159\u00EDpravku nebo komponenty obalu;\nvrozen\u00E1 abnormalita metabolismu aminokyselin;\npatologicky zv\u00FD\u0161en\u00E9 koncentrace sod\u00EDku, drasl\u00EDku, ho\u0159\u010D\u00EDku, v\u00E1pn\u00EDku a/nebo fosforu v plazm\u011B;\nz\u00E1va\u017En\u00E1 hyperglyk\u00E9mie.\nP\u0159id\u00E1n\u00ED lipid\u016F (pod\u00E1n\u00ED p\u0159\u00EDpravku NUMETA ve form\u011B aktivovan\u00E9ho 3komorov\u00E9ho vaku pro intraven\u00F3zn\u00ED emulzi) je kontraindikov\u00E1no v\u00A0n\u00E1sleduj\u00EDc\u00EDch dal\u0161\u00EDch klinick\u00FDch stavech:\nz\u00E1v\u00E1\u017En\u00E1 hyperlipid\u00E9mie nebo z\u00E1va\u017En\u00E9 poruchy metabolizmu lipid\u016F charakterizovan\u00E9 hypertriglycerid\u00E9mi\u00ED.\n"@cs . . "Kontraindikace"@cs . . "004.003" . .